The balm of Gilead: is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?
Must treatment be provided to subjects who acquire HIV during the course of a prevention study? An analysis of ethical foundation, regulation, and recent argumentation provides no basis for the obligation. We outline an alternative approach to the problem based on moral negotiation.
Weijer
Charles
C
Department of Philosophy, Talbot College, the University of Western Ontario, Canada.
Leblanc
Guy J
GJ
D019380:Anti-HIV Agents; D002986:Clinical Trials as Topic / Q000941:ethics*; D035881:Compensation and Redress / Q000941:ethics*; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D006679:HIV Seropositivity; D006801:Humans; D007391:International Cooperation; D008297:Male; D028681:Moral Obligations; D017008:Negotiating
D019380:Anti-HIV Agents